SN.L vs VCEL
SN.L: A global medical technology leader focused on restoring patient mobility through advanced orthopedic, sports medicine, and wound care solutions. VCEL: Vericel is a commercial-stage biotechnology company that develops and markets autologous cell therapies for the treatment of severe burns and cartilage damage in the knee.
Side-by-side fundamentals
| Metric | SN.L | VCEL | Edge |
|---|---|---|---|
| Price as of 2026-08-20 close | £10.74 | $42.68 | |
| Market cap as of 2026-08-24 | n/a | $2.2B | |
| P/E as of 2026-08-24 | n/a | 93.45 | |
| PEG as of 2026-08-24 | n/a | 0.36 | |
| Net margin as of 2026-08-24 | n/a | +7.9% | |
| Gross margin as of 2026-08-24 | n/a | +74.6% | |
| Operating margin as of 2026-08-24 | n/a | +6.0% | |
| ROE as of 2026-08-24 | n/a | +6.9% | |
| ROA as of 2026-08-24 | n/a | +5.0% | |
| Debt / equity as of 2026-08-24 | n/a | 0.00 | |
| Revenue growth (YoY) as of 2026-08-24 | n/a | +22.9% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +18.9% | |
| Beta as of 2026-08-24 | n/a | 1.04 | |
| 1-year return as of 2026-08-20 close | -22.8% | +20.4% | VCEL higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.